Pharma&

From Wikipedia, the free encyclopedia
pharma&
TypeGmbH
IndustryPharmaceutical
Founded2017
FounderFrank Rotmann, Elmar Zagler[1]
HeadquartersVienna, Austria and Zug, Switzerland
Key people
Frank Rotmann, Elmar Zagler[1]
ProductsPegasys
Revenuen.a.
Number of employees
n.a.
Websitewww.pharmaand.com

pharma& is an Austrian, Swiss, European pharmaceutical firm than ensures the long-term availability of established original drugs, (that were originally protected by chemical patents), distributes most of them worldwide and develops them further. The company pursues a global buy-and-build strategy. The drug Pegasys (peginterferon alfa-2a) alone, which was acquired from Roche in 2021, is estimated to generate sales of around 100 million EUR.[2] The purchase price was - according to Roche - CHF 191 million.[3]

Company background[]

As part of their product life cycle (life-cycle management), certain drugs lose their appeal to the companies that originally researched them. A typical example is the drug Pegasys: around the turn of the millennium, interferons were pioneering biological products. They are still used today in numerous indications such as skin cancer, hepatitis C and / or multiple sclerosis, where they have therapeutic value. And yet, due to changes in clinical practice - antiviral hepatitis drugs such as sofosbuvir have become much more important - Roche announced that it would withdraw the interforn drug Pegasys from the market worldwide,[4] but subsequently sold the worldwide rights to pharma&, that ensures supply in the medium and long term almost worldwide (excluding China and Japan).[5]. Strategically, a drug such as Pegasys no longer fits into the product portfolio of such a research-oriented company as Roche.

Pegasys was a so-called blockbuster: in 2009 - 2014 it made sales of well over one billion CHF. As recently as 2017, it generated well over CHF 100 million in sales.[2] In Roche's 2021 half-year report, sales proceeds are reported at CHF 191 million.[3]

Regardless of whether it is a former blockbuster or a niche product, pharma& acquires the registration and trademark rights of such drugs and keeps them available for doctors and patients worldwide. In most cases, these are brands that are still known to specialists as originals but have lost their appeal for the original manufacturer. They may even be medicines that have been included in the World Health Organization's List of Essential Medicines

Products[]

  • Anafranil (clomipramine) - rights acquired in numerous (<20) European countries by Novartis - included in the WHO Essential Medicines List in the category obsessive compulsive disorders.
  • Androskat (papaverine) - rights acquired in the Netherlands from Takeda.
  • Asacol (mesalazine) - rights acquired in Belgium and the Netherlands from Takeda
  • Dridase (oxybutynin) syrup - rights acquired in Belgium and the Netherlands|Netherlands from Sanofi and Takeda
  • Emselex (darifenacin) - rights in Europe acquired from Norgine, originally developed by Pfizer
  • Euphyllin (theophylline)- rights in some European countries acquired by AstraZeneca, originally developed by Altana/Byk Gulden
  • Pegasys (peginterferon alfa-2a) - former manufacturer: Roche - included in WHO essential medicines list

Shareholdings[]

  • Dewact Labs
  • Heritage Biologics
  • Loba Feinchemie GmbH

References[]

  1. ^ a b www.pharmaand.com, Company Website, Retrieved 4 December 2021
  2. ^ a b "Umsatz von Roche mit dem Medikament Pegasys in den Jahren 2009 bis 2017". de.statista.com. Retrieved 4 December 2021.
  3. ^ a b "HALF-YEAR REPORT 2021, p.20" (PDF). www.roche.com. Retrieved 4 December 2021.
  4. ^ "Verzichtserklärung der Zulassung - Mittelfristig läuft Pegasys aus" (PDF). www.roche.de (German). Retrieved 4 December 2021.
  5. ^ "Pegasys (Peginterferon alfa-2a) langfristig weiterhin erhältlich" (PDF). www.roche.de (German). Retrieved 4 December 2021.

External links[]

Retrieved from ""